We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The FDA has revealed that two of its prominent Directors are set to retire from the agency, leaving three of its 19 drug review divisions without permanent figures to lead them...